Treatment with tofacitinib appears to increase the risk of herpes zoster (HZ) compared with placebo, according to a recent study. The risk factors for heightened risk are Asian descent, increasing age, higher dose and prior biologic exposure.
The use of pulsed dye laser (PDL) in the treatment of acne vulgaris and acne erythema in young adults yields no significant improvement, but leads to high satisfaction among patients, according to a study.
There is a significant and disease severity‒dependent increased risk of developing conjunctivitis, keratitis and keratoconus in adults with atopic dermatitis (AD) compared with the general population, according to a recent study.
Melanocyte-keratinocyte transplantation procedure (MKTP) confers satisfactory long-term repigmentation in patients with leukoderma, with repigmentation lasting for at least 72 months, reports a recent study.
New drug applications approved by US FDA as of 1 - 15 Feb 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.